0.233
0.00 (1.39%)
| Previous Close | 0.230 |
| Open | 0.230 |
| Volume | 2,952,871 |
| Avg. Volume (3M) | 3,674,037 |
| Market Cap | 28,185,310 |
| Price / Sales | 53.22 |
| 52 Weeks Range | |
| Earnings Date | 15 May 2026 |
| Diluted EPS (TTM) | 4.09 |
| Current Ratio (MRQ) | 0.720 |
| Operating Cash Flow (TTM) | -64.05 M |
| Levered Free Cash Flow (TTM) | -35.91 M |
| Return on Assets (TTM) | -122.34% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Outlook Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.88 |
|
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 38.31% |
| % Held by Institutions | 16.89% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Gilpin Wealth Management, Llc | 31 Mar 2026 | 600,162 |
| Warberg Asset Management Llc | 31 Mar 2026 | 275,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 6.00 (Ascendiant Capital, 2,472.90%) | Buy |
| Median | 1.00 (328.82%) | |
| Low | 0.500 (HC Wainwright & Co., 114.41%) | Hold |
| Average | 2.50 (972.04%) | |
| Total | 1 Buy, 2 Hold | |
| Avg. Price @ Call | 0.418 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Ascendiant Capital | 11 Mar 2026 | 6.00 (2,472.90%) | Buy | 0.434 |
| Chardan Capital | 18 Feb 2026 | 1.00 (328.82%) | Hold | 0.410 |
| HC Wainwright & Co. | 18 Feb 2026 | 0.500 (114.41%) | Hold | 0.410 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |